Despite exhibiting better outcomes than chemotherapy also in PD-L1 negative NSCLC, FDA approved the immunotherapy combination as first-line therapy only for PD-L1 positive disease [52]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.